
RealRate

PHARMACEUTICAL 2022

REGENERX BIOPHARMACEUTICALS INC Rank 436 of 466



RealRate

PHARMACEUTICAL 2022

REGENERX BIOPHARMACEUTICALS INC Rank 436 of 466

The relative strengths and weaknesses of REGENERX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 33% points. The greatest weakness of REGENERX BIOPHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -226%, being 304% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	1,252
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	430
Liabilities, Non-Current	1,948
Other Assets	33
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,137
Other Net Income	-269
Other Revenues	77
Property and Equipment	0
Research and Development	6.6
Selling, General and Administrative Expense	1,399

Output Variable	Value in 1000 USD
Assets	1,285
Liabilities	3,515
Expenses	1,405
Revenues	77
Stockholders Equity	-2,230
Net Income	-1,598
Comprehensive Net Income	-1,598
Economic Capital Ratio	-226%

